Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Research & Development (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Research & Development for 13 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 22.14% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Dec 2025, down 0.61% year-over-year, with the annual reading at $37.4 million for FY2025, 0.61% down from the prior year.
  • Research & Development for Q4 2025 was $7.4 million at Theravance Biopharma, down from $8.1 million in the prior quarter.
  • The five-year high for Research & Development was $67.6 million in Q1 2021, with the low at $7.4 million in Q4 2025.
  • Average Research & Development over 5 years is $18.6 million, with a median of $10.2 million recorded in 2024.
  • The sharpest move saw Research & Development tumbled 77.44% in 2022, then increased 27.7% in 2025.
  • Over 5 years, Research & Development stood at $31.2 million in 2021, then tumbled by 50.85% to $15.3 million in 2022, then crashed by 45.84% to $8.3 million in 2023, then rose by 13.71% to $9.5 million in 2024, then fell by 22.14% to $7.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $7.4 million, $8.1 million, and $10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.